ABSTRACT
MET gene is a proto-oncogene, which encodes MET protein with tyrosine kinase activity. After binding to its ligand, hepatocyte growth factor, MET protein can induce MET dimerization and activate downstream signaling pathways, which plays a crucial role in tumor formation and metastasis. Savolitinib, as a specific tyrosine kinase inhibitor (TKI) targeting MET, selectively inhibits the phosphorylation of MET kinase with a significant inhibitory effect on tumors with MET abnormalities. Based on its significant efficacy shown in the registration studies, savolitinib was approved for marketing in China on June 22, 2021 for the treatment of advanced non-small cell lung cancer with MET 14 exon skipping mutations. In addition, many studies have shown that MET TKIs are equally effective in patients with advanced solid tumors with MET gene amplification or MET protein overexpression, and relevant registration clinical studies are ongoing. The most common adverse reactions during treatment with savolitinib include nausea, vomiting, peripheral edema, pyrexia, and hepatotoxicity. Based on two rounds of extensive nationwide investigations to guide clinicians, the consensus is compiled to use savolitinib rationally, prevent and treat various adverse reactions scientifically, and improve the clinical benefits and quality of life of patients. This consensus was prepared under the guidance of multidisciplinary experts, especially including the whole-process participation and valuable suggestions of experts in Traditional Chinese Medicine, thus reflecting the clinical treatment concept of integrated Chinese and western medicines.
Subject(s)
Humans , Carcinoma, Non-Small-Cell Lung/genetics , Lung Neoplasms/pathology , Consensus , Quality of Life , Proto-Oncogene Proteins c-met/genetics , Protein Kinase Inhibitors/adverse effects , Drug-Related Side Effects and Adverse Reactions , MutationABSTRACT
A validated new, simple and highly sensitive reversed-phase HPLC method is developed for studying the pharmacokinetics of germacrone after intravenous administration of zedoary turmeric oil (ZTO) oil-in-water microemulsion. The method did not require a complex and expensive equipment. A high extraction recovery (>80%) of germacrone was obtained. Linear calibration curves obtained with the peak-area ratio (y) of germacrone to internal standard (tanshinoneIIA) versus drug concentration (x) were found to be linear between 8.08 and 808 ng/ml. The limit of quantitation was 8.08 ng/ml. The monitored compounds were completely separated from others in ZTO and from endogenous species in plasma by HPLC. Pharmacokinetic investigations were performed on 18 male rabbits after intravenous administration of ZTO microemulsion via the ear vein at germacrone doses of 3.2, 6.4 and 9.6 mg/kg. The plasma concentration-time data fit to a two-compartment intravenous model with a weight of 1/C(2) (C: germacrone concentration in plasma). Germacrone exhibited linear pharmacokinetics after intravenous administration of ZTO microemulsion to rabbits over the germacrone dose range 3.2-9.6 mg/ml.
Subject(s)
Chromatography, High Pressure Liquid/methods , Curcuma/chemistry , Plant Oils/administration & dosage , Sesquiterpenes, Germacrane/blood , Animals , Area Under Curve , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/pharmacokinetics , Injections, Intravenous , Male , Metabolic Clearance Rate , Rabbits , Reproducibility of Results , Sesquiterpenes, Germacrane/pharmacokineticsABSTRACT
<p><b>OBJECTIVE</b>To develop a new method for the determination of cholesteryl palmitate in Oviductus Ranae.</p><p><b>METHOD</b>A HPLC method was set up, using Zorbax Silica column and cyclohexane-diethyl ether (40:1) as mobile phase with a flow rate of 1.0 mL x min(-1), and the UV detection wavelength was 203 nm.</p><p><b>RESULT</b>The calibration curve was linear over the range of 0.60-8.92 microg (r = 0.9997), the average recovery of the method was 98.4%. RSD 1.8% (n = 6).</p><p><b>CONCLUSION</b>The results showed that method was reliable and accurate.</p>
Subject(s)
Animals , Female , Cholesterol Esters , Chromatography, High Pressure Liquid , Methods , Materia Medica , Chemistry , Oviducts , Chemistry , Quality Control , Rana temporariaABSTRACT
<p><b>OBJECTIVE</b>Studies on the substance with nourishment Yin for a reasonable and rational auality appraise for turtleback.</p><p><b>METHOD</b>To separate by chromatography and identifying with MS, 1H NMR, 13C NMR, IR.</p><p><b>RESULT</b>Two compounds were separated and identified as hexadecanoyl cholesterol ester and cholesterol.</p><p><b>CONCLUSION</b>The two compounds are isolated from turtleback for the first time.</p>